RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang a Canadian-American scientist. RemeGen is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States.
The World’s First Innovative Dual-Target Biological Medication to Treat Systemic Lupus Erythematosus
The First Independently Developed Novel ADC Drug in China
【2024.05.07】 Monthly Returns Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
【2024.04.26】 [Overseas Regulatory Announcement - Other] An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
On June 27, the world-renowned oncology journal Journal of Clinical Oncology (JCO) published the full research paper from a Phase II RCTS trial online. The study evaluated the combination of Disitamab Vedotin, Tislelizumab, and S-1 as a first-line th
Address: No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.
Telephone:（+86）535-3573511
News
First patient enrolled in Telitacicept IgA nephropathy PhaseⅡclinical trial in the U.S.
官方微信
官方微信